WO2007095279A3 - Dual nanoparticle assay for detection and separation of biological species - Google Patents

Dual nanoparticle assay for detection and separation of biological species Download PDF

Info

Publication number
WO2007095279A3
WO2007095279A3 PCT/US2007/003883 US2007003883W WO2007095279A3 WO 2007095279 A3 WO2007095279 A3 WO 2007095279A3 US 2007003883 W US2007003883 W US 2007003883W WO 2007095279 A3 WO2007095279 A3 WO 2007095279A3
Authority
WO
WIPO (PCT)
Prior art keywords
detection
cells
aptamer
methods
aptamers
Prior art date
Application number
PCT/US2007/003883
Other languages
French (fr)
Other versions
WO2007095279A2 (en
Inventor
Weihong Tan
Joshua Elliott Smith
Colin Donnell Medley
Joshua Kenneth Herr
Dihua Shangguan
Original Assignee
Univ Florida
Weihong Tan
Joshua Elliott Smith
Colin Donnell Medley
Joshua Kenneth Herr
Dihua Shangguan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida, Weihong Tan, Joshua Elliott Smith, Colin Donnell Medley, Joshua Kenneth Herr, Dihua Shangguan filed Critical Univ Florida
Publication of WO2007095279A2 publication Critical patent/WO2007095279A2/en
Publication of WO2007095279A3 publication Critical patent/WO2007095279A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ecology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The subject invention provides novel methods, kits, and compositions for use in detecting, quantifying, and/or separating target cells in a sample. In one embodiment, methods for the rapid collection and detection of leukemia cells are provided using a novel dual nanoparticle assay with aptamers as the molecular recognition element. Aptamer sequences are prepared using a cell based SELEX strategy, where the aptamers are specific for CCRF-CEM acute leukemia (AL) cells. Such aptamers preferably demonstrate a high degree of specificity or selectivity for AL cells in complex mixtures, including whole blood samples. According to one embodiment of the invention, aptamer modified magnetic nanoparticles are used for target cell extraction, while aptamer modified fluorescent nanoparticles are simultaneously added for sensitive cell detection. Combining two types of nanoparticle-based screening techniques allows for rapid, selective, and sensitive detection not possible by using either particle alone. In a related embodiment, fluorescent nanoparticles amplify the signal intensity corresponding to a single aptamer binding event, resulting in improved sensitivity over methods using individual dye labeled probes. In addition, aptamer modified magnetic nanoparticles allow for rapid extraction of target cells not possible with other separation methods. Fluorescent imaging and flow cytometry are used for cellular detection to demonstrate the application of this method for medical diagnostics.
PCT/US2007/003883 2006-02-14 2007-02-14 Dual nanoparticle assay for detection and separation of biological species WO2007095279A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77326706P 2006-02-14 2006-02-14
US60/773,267 2006-02-14

Publications (2)

Publication Number Publication Date
WO2007095279A2 WO2007095279A2 (en) 2007-08-23
WO2007095279A3 true WO2007095279A3 (en) 2007-11-15

Family

ID=38372106

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/003883 WO2007095279A2 (en) 2006-02-14 2007-02-14 Dual nanoparticle assay for detection and separation of biological species

Country Status (1)

Country Link
WO (1) WO2007095279A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105120849A (en) * 2013-03-14 2015-12-02 Ran生物技术公司 Methods and materials for detection of biologicals

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008064667B4 (en) 2008-07-15 2011-06-09 Lzh Laserzentrum Hannover E.V. Process for the preparation of a detection conjugate
CN102023147B (en) * 2010-09-29 2012-02-22 江南大学 Method for detecting ochratoxin A by magnetic separation of adapter-functionalized magnetic nano material and marking of up-conversion fluorescent nano material
US9777264B2 (en) 2011-11-03 2017-10-03 Qiagen Gaithersburg, Inc. Materials and method for immobilizing, isolating, and concentrating cells using carboxylated surfaces
US10105681B2 (en) 2013-03-14 2018-10-23 Ran Biotechnologies, Inc. Methods and materials for microorganism capture
CN103940792B (en) * 2014-02-20 2016-06-22 江南大学 A kind of method simultaneously detecting three kinds of food-borne pathogens based on polychrome up-conversion fluorescent marking
CN107614565B (en) 2015-04-21 2021-04-09 Ran生物技术公司 Fluorinated surfactants
CN104818279A (en) * 2015-04-23 2015-08-05 河南省农业科学院 Ochratoxin A nucleic acid adapter and application thereof to sample magnetic separation preprocessing
US20210145981A1 (en) * 2015-08-20 2021-05-20 Robert E. Sandstrom Method of attacking target cells
JP7254349B2 (en) * 2016-10-26 2023-04-10 インテグレーテッド ナノ－テクノロジーズ，インコーポレイティド System and method for optical detection of biomolecular targets
CN107841527B (en) * 2017-11-07 2022-01-18 天津科技大学 Fluorescence detection method for detecting thrombin by using aptamer and magnetic material
CN114018789A (en) * 2021-10-08 2022-02-08 武汉大学 Acute leukemia typing method based on imaging flow cytometry detection and machine learning
WO2024175169A1 (en) * 2023-02-20 2024-08-29 STILLER, Olaf Method for directly detecting the presence of a test substance

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020037506A1 (en) * 2000-04-18 2002-03-28 Yun Lin Aptamer based two-site binding assay
US6777186B2 (en) * 1996-07-29 2004-08-17 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US20040166505A1 (en) * 1999-05-07 2004-08-26 Quantum Dot Corporation Method of detecting an analyte in a sample using semiconductor nanocrystals as a detectable label

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777186B2 (en) * 1996-07-29 2004-08-17 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US20040166505A1 (en) * 1999-05-07 2004-08-26 Quantum Dot Corporation Method of detecting an analyte in a sample using semiconductor nanocrystals as a detectable label
US20020037506A1 (en) * 2000-04-18 2002-03-28 Yun Lin Aptamer based two-site binding assay

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105120849A (en) * 2013-03-14 2015-12-02 Ran生物技术公司 Methods and materials for detection of biologicals
CN105120849B (en) * 2013-03-14 2020-08-21 Ran生物技术公司 Methods and materials for detecting biological substances

Also Published As

Publication number Publication date
WO2007095279A2 (en) 2007-08-23

Similar Documents

Publication Publication Date Title
WO2007095279A3 (en) Dual nanoparticle assay for detection and separation of biological species
US11899024B2 (en) Treatment and diagnosis of parkinson's disease using isolated and enriched populations of biofluid-derived extracellular vesicles
Salvianti et al. The pre-analytical phase of the liquid biopsy
Contreras-Naranjo et al. Microfluidics for exosome isolation and analysis: enabling liquid biopsy for personalized medicine
KR102304167B1 (en) Selective delivery of material to cells
Csordas et al. Detection of proteins in serum by micromagnetic aptamer PCR (MAP) technology
Ulep et al. Smartphone based on-chip fluorescence imaging and capillary flow velocity measurement for detecting ROR1+ cancer cells from buffy coat blood samples on dual-layer paper microfluidic chip
WO2008008785A3 (en) Ultra-sensitive detection of analytes
EP3246703A1 (en) Method and kit for capturing extracellular vesicles (evs) on a solid surface
Zhou et al. Multiplexed profiling of biomarkers in extracellular vesicles for cancer diagnosis and therapy monitoring
Salmond et al. Nanoscale flow cytometry for immunophenotyping and quantitating extracellular vesicles in blood plasma
CN101313218A (en) Magnetic biosensor for determination of enzymic activity
CN113640515B (en) Method and kit for jointly detecting exosomes by utilizing multiple markers
Zhu et al. An ultrasensitive flow cytometric immunoassay based on bead surface-initiated template-free DNA extension
CN110945145B (en) Microvesicle nucleic acids and/or proteins and their use as markers for renal transplant rejection
CN110468190A (en) A kind of self-assembly probe based on change of configuration and its markless detection method for excretion body
CN115038968A (en) Multiple analyte fecal antigen testing
JP2023100770A (en) Manufacturing device and manufacturing method for exosome liquid biopsy sample
Wu et al. One-step and label-free ratiometric fluorescence assay for the detection of plasma exosome towards cancer diagnosis
Wang et al. Single microbead-based fluorescent aptasensor (SMFA) for direct isolation and in situ quantification of exosomes from plasma
KR102498862B1 (en) Method for analyzing exosomes in liquid biopsy sample
KR102323360B1 (en) Apparatus and method for preparing a liquid biopsy sample with an exosome subpopulation or the lower
US20120112097A1 (en) Method and apparatus for quantitative analysis of the extent of membrane fouling by using fluorescent protein structures
WO2013003898A1 (en) Method for detection of cancer in a patient
CN116930497B (en) Kit for detecting exosome HER2 membrane protein and mRNA, application thereof and detection method

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07750704

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 07750704

Country of ref document: EP

Kind code of ref document: A2